Atherosclerosis -- new targets and therapeutics

Area of Science:

• Cardiovascular Medicine
• Inflammation Research
• Drug Development

Background:

• Atherosclerosis is an inflammatory condition where cells and proteins contribute to lesion development.
• Inflammatory markers predict atherosclerotic lesion progression and cardiovascular events.
• Statins reduce inflammation markers, but this effect is independent of LDL lowering.

Purpose of the Study:

• To review scientific advances in atherosclerosis treatment.
• To examine current and emerging therapeutic approaches for cardiovascular disease prevention.
• To discuss direct disease modifiers beyond traditional risk factor reduction.

Main Methods:

• Review of scientific literature on atherosclerosis.
• Analysis of pre-clinical and clinical development of novel therapeutic molecules.
• Examination of targets including cytokine antagonists, adhesion molecule inhibitors, reverse cholesterol transport proteins, and matrix remodeling regulators.

Main Results:

• Research is shifting towards therapies directly targeting atherosclerotic processes.
• Emerging targets include proteins involved in reverse cholesterol transport (e.g., ApoA1/apoE/ABCA1) and lipid metabolism (e.g., ACAT, LpPLA2).
• Modulation of matrix metalloproteinases and heparan sulfate proteoglycans are also key areas of investigation.

Conclusions:

• Current atherosclerosis treatment involves risk factor reduction and direct disease modification.
• Novel therapeutic strategies aim to directly impact the inflammatory and metabolic pathways of atherosclerosis.
• These approaches hold promise for the future prevention of cardiovascular disease.